Showing results (1651-1660 of 1,712) with videos related to

Sort By:
Pageof 172
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2026
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 StudyRaphael J Landovitz, Yvett Pinedo, Federico Hinestrosa, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
Science (New York, N.Y.)|December 15, 2018
Genome-wide de novo risk score implicates promoter variation in autism spectrum disorderJoon-Yong An, Kevin Lin, Lingxue Zhu, et al.
American Journal of Human Genetics|March 26, 2025
Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatmentsDavid Cheerie, Margaret M Meserve, Danique Beijer, et al.
Global Change Biology|July 15, 2020
Drivers of future alien species impacts: An expert-based assessmentFranz Essl, Bernd Lenzner, Sven Bacher, et al.
Nature|January 30, 2009
Southern Ocean deep-water carbon export enhanced by natural iron fertilizationRaymond T Pollard, Ian Salter, Richard J Sanders, et al.
American Journal of Human Genetics|March 29, 2016
Frequency and Complexity of De Novo Structural Mutation in AutismWilliam M Brandler, Danny Antaki, Madhusudan Gujral, et al.
Nature Metabolism|March 20, 2024
Trigonelline is an NAD<sup>+</sup> precursor that improves muscle function during ageing and is reduced in human sarcopeniaMathieu Membrez, Eugenia Migliavacca, Stefan Christen, et al.
Science (New York, N.Y.)|January 20, 2016
De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomaliesJason Homsy, Samir Zaidi, Yufeng Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Pageof 172